- $853.55m
- $2.98m
- $87.24m
- 86
- 17
- 71
- 59
C2019 December 31st | C2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 23.8 | 46.7 | 74.4 | 86.7 | 87.2 |
Cost of Revenue | |||||
Gross Profit | -17.6 | -25.8 | -17.5 | 15.4 | 11.9 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 177 | 266 | 635 | 260 | 195 |
Operating Profit | -153 | -219 | -561 | -173 | -108 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 1,166 | -73.3 | -397 | -121 | -73.7 |
Provision for Income Taxes | |||||
Net Income After Taxes | 1,166 | -74.6 | -397 | -155 | -70.4 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | 1,167 | -73.1 | -396 | -169 | -74 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 1,142 | -73.1 | -396 | -169 | -74 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 3.7 | -0.132 | -0.43 | -0.294 | -0.135 |